Sugi Predict

Sugi Predict / Compounds / SCHEMBL3835930

SCHEMBL3835930

SCHEMBL3835930

CN(C)CC(C)(C)CN(Cc1ccc(C(=O)Nc2ccccc2N)cc1)C(=O)Nc1ccc(N(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 20/20 0.55
▸ HDAC3 O15379 7/20 0.55
▸ HDAC2 Q92769 6/20 0.55
▸ NCOR2 Q9Y618 3/20 0.55
▸ HDAC4 P56524 2/20 0.45
▸ HDAC7 Q8WUI4 2/20 0.45
▸ HDAC10 Q969S8 2/20 0.45
▸ HDAC11 Q96DB2 2/20 0.45
▸ HDAC8 Q9BY41 2/20 0.45
▸ HDAC6 Q9UBN7 2/20 0.45
▸ HDAC9 Q9UKV0 2/20 0.45
▸ HDAC5 Q9UQL6 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3829614 0.91 HDAC1 (0.55) HDAC1HDAC3HDAC2NCOR2
SCHEMBL2471481 0.88 HDAC1 (0.50) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL3835736 0.88 HDAC1 (0.58) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL3830335 0.88 HDAC1 (0.58) HDAC1HDAC3HDAC2NCOR2HDAC6
SCHEMBL2477337 0.87 HDAC1 (0.51) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL3834510 0.87 HDAC1 (0.59) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL2500042 0.86 HDAC1 (0.43) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL2474043 0.86 HDAC1 (0.56) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL2474131 0.86 HDAC1 (0.56) HDAC1HDAC3HDAC2NCOR2HDAC4
SCHEMBL2471328 0.86 HDAC1 (0.58) HDAC1HDAC3HDAC2NCOR2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 — — US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 — — US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 — — US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 — — US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 — — US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 — — US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885HDAC3 795/4885HDAC2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.